kTMP in Chronic Stroke

NCT ID: NCT07277595

Last Updated: 2025-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-01

Study Completion Date

2030-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

kTMP, kilohertz transcutaneous magnetic perturbations, is a low intensity transcranial magnetic stimulation technique that will be used in this study to promote arm/hand rehabilitation in patients who have been disabled by stroke.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Chronic Stroke Patients Arm Weakness as a Consequence of Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Treatment

Active treatment with kTMP for 18 weeks

Group Type ACTIVE_COMPARATOR

kTMP 18 weeks

Intervention Type DEVICE

Participants receive kTMP active stimulation for 18 weeks

Crossover Treatment

Initial 9 weeks will receive sham kTMP treatment, followed by 9 weeks of active kTMP treatment.

Group Type OTHER

kTMP sham stimulation 9 weeks + active stimulation 9 weeks

Intervention Type DEVICE

kTMP 9 weeks sham-kTMP stimulation, followed by 9 weeks active kTMP stimulation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

kTMP sham stimulation 9 weeks + active stimulation 9 weeks

kTMP 9 weeks sham-kTMP stimulation, followed by 9 weeks active kTMP stimulation

Intervention Type DEVICE

kTMP 18 weeks

Participants receive kTMP active stimulation for 18 weeks

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults age 18-80 years old who have had a stroke resulting in hemiplegia
* Ability to communicate, understand, and give appropriate consent
* Other criteria may apply

Exclusion Criteria

* Significant cognitive impairment
* inability to adhere to the study protocol or provide informed consent
* pregnancy
* additional criteria may apply
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

Sponsor Role collaborator

University of California, San Francisco

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Karunesh Ganguly, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California, San Francisco

San Francisco, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Karunesh Ganguly, MD, PhD

Role: CONTACT

415-514-1252

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R44NS139730

Identifier Type: NIH

Identifier Source: secondary_id

View Link

25-43524

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.